Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest update is out from Kronos Bio ( (KRON) ).
Kronos Bio, Inc. is undergoing a significant transformation with an 83% workforce reduction aimed at strategic cost containment by December 31, 2024, incurring an expected $3.7 million in severance expenses. Concurrently, Norbert Bischofberger resigns as CEO, with Deborah Knobelman stepping up as President and Interim CEO, receiving increased compensation and a special bonus tied to potential company control changes. These shifts indicate a pivotal moment for Kronos Bio amidst anticipated financial restructuring.
See more insights into KRON stock on TipRanks’ Stock Analysis page.
